Abstract #0289

Large-scale radiomic profiling of glioblastoma identifies an imaging signature for predicting and stratifying antiangiogenic treatment response.

Philipp Kickingereder¹, Michael Götz², John Muschelli³, Antje Wick⁴, Ulf Neuberger⁵, Russell T Shinohara⁶, Alexander Radbruch⁷, Heinz-Peter Schlemmer⁷, Wolfgang Wick⁴, Martin Bendszus⁵, Klaus H Maier-Hein², and David Bonekamp⁷

¹Department of Neuroradiology, University Hospital Heidelberg, Heidelberg, Germany, ²Division Medical and Biological Informatics, DKFZ - German Cancer Research Center, Heidelberg, Germany, ³Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States, ⁴Department of Neurology, University of Heidelberg Medical Center, Heidelberg, Germany, ⁵Department of Neuroradiology, University of Heidelberg Medical Center, Heidelberg, Germany, ⁶Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States, ⁷Department of Radiology, DKFZ - German Cancer Research Center, Heidelberg, Germany

To analyze the potential of radiomics, an emerging field of research that aims to utilize the full potential of medical Imaging (1,2), for predicting and stratifying treatment response to antiangiogenic therapy in patients with recurrent glioblastoma.

This abstract and the presentation materials are available to members only; a login is required.

Join Here